InsidersTradesSigma
Total declarations
Company
▲ Purchases (31 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
31
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+24.6%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Alstodt Lance, Chairman & CEO. Director active across 1 company, notably BioRestorative Therapies, Inc.. In total, 36 filings have been published. Breakdown: 31 buys · 0 sell. Total volume traded: €91k. History available since 16 November 2021. The latest transaction was filed on 6 October 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Alstodt Lance
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations36 total
15,625 shares@ US$1.6013.8% of flowCommon StockSEC:0001021771-25-000140:0
17,633 shares@ US$1.3913.3% of flowCommon StockSEC:0001021771-24-000077:0
2,200 shares@ US$1.702.4% of flowCommon StockSEC:0001021771-23-000096:0
Canonical exit: 14 Dec 2023 (T+90)
800 shares@ US$1.53250.7% of flowCommon StockSEC:0001021771-23-000090:0
Canonical exit: 12 Dec 2023 (T+90)
2,887 shares@ US$1.963.1% of flowCommon StockSEC:0001021771-23-000088:0
Canonical exit: 5 Dec 2023 (T+90)
4,200 shares@ US$2.445.5% of flowCommon StockSEC:0001140361-23-036103:0
Canonical exit: 23 Oct 2023 (T+90)
6,729 shares@ US$2.9210.8% of flowCommon StockSEC:0001021771-23-000026:0
374 shares@ US$2.990.6% of flowCommon StockSEC:0001567619-23-003875:0
400 shares@ US$3.10340.7% of flowCommon StockSEC:0001567619-23-001697:0
Canonical exit: 2 May 2023 (T+90)
200 shares@ US$3.010.3% of flowCommon StockSEC:0001567619-23-001399:0
Canonical exit: 27 Apr 2023 (T+90)
100 shares@ US$3.100.2% of flowCommon StockSEC:0001567619-23-001186:0
Canonical exit: 20 Apr 2023 (T+90)
100 shares@ US$3.170.2% of flowCommon StockSEC:0001567619-23-001186:1
Canonical exit: 20 Apr 2023 (T+90)
200 shares@ US$3.130.3% of flowCommon StockSEC:0001567619-23-001056:0
Canonical exit: 18 Apr 2023 (T+90)
100 shares@ US$3.080.2% of flowCommon StockSEC:0001567619-23-000770:0
Canonical exit: 9 Apr 2023 (T+90)
200 shares@ US$3.020.3% of flowCommon StockSEC:0001567619-22-022055:0
Canonical exit: 23 Mar 2023 (T+90)
1,800 shares@ US$2.98613.0% of flowCommon StockSEC:0001567619-22-021408:0
Canonical exit: 7 Mar 2023 (T+90)
1,000 shares@ US$2.87651.6% of flowCommon StockSEC:0001567619-22-020651:0
Canonical exit: 16 Feb 2023 (T+90)
100 shares@ US$2.990.2% of flowCommon StockSEC:0001567619-22-017754:0
Canonical exit: 21 Dec 2022 (T+90)
700 shares@ US$2.951.2% of flowCommon StockSEC:0001567619-22-013928:0
Canonical exit: 10 Oct 2022 (T+90)
1,100 shares@ US$3.09810.066% mcap3.5% of flowCommon StockSEC:0001567619-22-013553:0
Canonical exit: 28 Sept 2022 (T+90)
600 shares@ US$3.731.4% of flowCommon StockSEC:0001567619-22-013067:0
Canonical exit: 14 Sept 2022 (T+90)
700 shares@ US$3.68221.6% of flowCommon StockSEC:0001567619-22-012910:0
Canonical exit: 13 Sept 2022 (T+90)
500 shares@ US$3.91191.2% of flowCommon StockSEC:0001567619-22-012867:0
Canonical exit: 12 Sept 2022 (T+90)
100 shares@ US$3.980.2% of flowCommon StockSEC:0001567619-22-012812:0
Canonical exit: 11 Sept 2022 (T+90)
100 shares@ US$3.920.2% of flowCommon StockSEC:0001567619-22-012812:1
Canonical exit: 11 Sept 2022 (T+90)
25 of 36 declarations
About Alstodt Lance
ALSTODT LANCE is Président-Directeur Général and has reported 36 filings in total. Across the 36 sampled filings, all relating to BioRestorative Therapies, Inc. on XNAS, the buy volume is EUR 91138, the sell volume is EUR 0, the date range runs from 2021-11-16 to 2025-10-20, and the modal transaction nature is Acquisition.
